Precision BioSciences (DTIL) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Precision BioSciences (DTIL) over the past year, gaining 76.2% versus a gain of 10.0%. Over five years, ORMP leads with a -80.2% price change compared with -97.9% for DTIL. Oramed Pharmaceuticals is the larger company by market cap ($181.8 million vs $172.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | ORMP |
|---|---|---|
| Share price | $6.25 | $4.37 |
| Market cap | $172.51M | $181.78M |
| 1-day change | +0.81% | -0.23% |
| YTD return | +50.24% | +53.33% |
| 1-year return | +10.04% | +76.21% |
| 5-year return | -97.87% | -80.19% |
| P/E ratio (TTM) | — | 1.06 |
| EPS (TTM) | $-1.35 | $4.13 |
| Dividend yield | 0.00% | 5.71% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $5.47 |
| 52-week low | $3.53 | $2.09 |
| Distance from 52-week high | -35.03% | -20.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +370.40% | +60.18% |
| Average volume | 293.42K | 192.76K |
| Shares outstanding | 27.60M | 41.60M |
| Employees | 67 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed DTIL by 66.2 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
DTIL vs ORMP FAQ
Which is bigger, Precision BioSciences or Oramed Pharmaceuticals?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $181.78M compared with $172.51M for Precision BioSciences (DTIL).
Which stock has performed better over the past year, DTIL or ORMP?
ORMP returned +76.21% over the past 12 months, compared with +10.04% for DTIL (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Precision BioSciences or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while Precision BioSciences does not currently pay a regular dividend.
Are Precision BioSciences and Oramed Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Precision BioSciences and Biotechnology: Pharmaceutical Preparations for Oramed Pharmaceuticals.